Pregled bibliografske jedinice broj: 667920
Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off?
Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off? // Wiener klinische Wochenschrift, 123 (2011), 23/24; 726-731 doi:10.1007/s00508-011-0099-4 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 667920 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off?
Autori
Badžek, Saša ; Kelović Lesko, Vesna ; Pleština, Stjepko ; Humar, Ines ; Veir, Zoran ; Mihaljević, Zoran
Izvornik
Wiener klinische Wochenschrift (0043-5325) 123
(2011), 23/24;
726-731
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
breast cancer; HER2/ECD; tumor markers
Sažetak
HER2 overexpression is well- established risk factor of worse prognosis in metastatic and early breast cancer. HER2 positivity can be determined from tumor tissue by immunohistochemical staining or by fluorescent in situ hybridization, or from serum by measuring concentration of HER2 receptor extracellular domain (HER2/ECD). HER2/ECD correlates well with worse prognosis in metastatic and locally advanced (stage III) disease if serum concentration is >15 ng/ml, but there are no consistent data for patients with early breast cancer. 41 patients with stage I and II breast cancer and 52 healthy controls were included into the study. HER2/ECD was determined before surgery and correlated with HER2/neu overexpression, Ki67, hormone receptor status and disease stage, and compared with value in healthy controls. Mean serum HER2/ECD concentration in patients was 8.62 ng/ml and 5.78 ng/ml in controls, and the difference was statistically significant (p = 0.000061). The best diagnostic cut-off value was 7.7 ng/ml, with 76.92% sensitivity and 72.92% specificity. Positive predictive value of the test was 69.77% and negative predictive value was 79.55%, with 74.71% of patients correctly classified. Serum HER2/ECD correlated with hormone receptors status, and no correlation with histological overexpression has been observed. Serum HER2/ECD concentration of ≥7.7 ng/ml has possible diagnostic value in stage I and II breast cancer. It should not be used as a determinant of HER2 positivity. Prognostic significance of HER2/ECD in early breast cancer, its correlation with hormone receptor status, and interconnection between hormone receptors and HER2 receptor signaling should be further analyzed, since it may have therapeutic implications.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1080058-0047 - Molekularni biljezi u solidnim tumorima - prediktivni i prognostički značaj (Pleština, Stjepko, MZOS ) ( CroRIS)
Ustanove:
Hrvatski veterinarski institut, Zagreb,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE